Patient Reported Outcomes Following Initiation of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes in a Specialist Endocrinology Practice of the LMC Diabetes Registry: The PROGRESS-Diabetes Study.

Clicks: 303
ID: 14073
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #18 of 50 articles by views in Diabetes research and clinical practice

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
To compare patient-reported outcomes and clinical outcomes in patients who initiated dulaglutide or liraglutide as part of usual clinical therapy.This observational study enrolled adults with type 2 diabetes who initiated dulaglutide or liraglutide between April 2017 and January 2018. A prospective patient cohort completed questionnaires at baseline and at their usual follow-up visit three to six months later. Clinical outcomes were assessed in a post-hoc retrospective analysis using propensity score matching.In the per-protocol analysis, 146 dulaglutide and 79 liraglutide patients had similar significant improvements in diabetes treatment satisfaction scores (dulaglutide 9.6 ± 1.1, p<0.001; liraglutide 10.6 ± 1.4, p<0.001) and follow-up scores for diabetes device satisfaction. Only dulaglutide had significant improvements in medication adherence scores. In the overall cohort, 754 matched patients showed similar reductions in A1C (dulaglutide -0.8% [9 mmol/mol]; liraglutide -0.7% [8 mmol/mol]). Liraglutide patients had a greater reduction in weight than those initiating dulaglutide (-2.8 kg vs. -1.8 kg; p<0.001).Patients who initiated dulaglutide or liraglutide in a real-world specialist practice had similar improvements in diabetes medication satisfaction and diabetes device satisfaction. Only dulaglutide patients had significant improvements in medication adherence scores. Both treatment cohorts had similar patterns of A1C change, and liraglutide had significantly greater weight loss, which are similar to findings from clinical trials.
Reference Key
brown2019patientdiabetes Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Brown, Ruth E;Abitbol, Alexander;Bajaj, Harpreet S;Goldenberg, Ronald;Khandwala, Hasnain;Abdel-Salam, Suzan;Aronson, Ronnie;
Journal Diabetes research and clinical practice
Year 2019
DOI
S0168-8227(19)30959-3
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.